Identification of recurrent GBM patients that may benefit from Bevacizumab and CCNU: A report from the BELOB trial by the Dutch Neurooncology Group

ABSTRACT: The results from the randomized phase II BELOB trial provided evidence for a potential benefit of bevacizumab (beva; a humanized monoclonal antibody against circulating VEGF-A) when added to CCNU chemotherapy in recurrent GBM patients. In this study, we have performed gene expression profiling (DASL and RNA-seq) on formalin fixed, paraffin embedded (FFPE) tumor material from patients treated within the BELOB trial to identify recurrent GBM patients who benefit most from combined beva/CCNU treatment. We first extensively validate the use of FFPE tissues for expression profiling on both DASL and RNA-seq. Our data show that tumors assigned to IGS-18 or â??classicalâ?? GBMs show a significant benefit in progression free survival (PFS) and a trend towards benefit in overall survival (OS) from b

ORGANISM(S): Homo sapiens

SUBMITTER: Pim French 

PROVIDER: E-GEOD-72951 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress